Resources
Life Molecular Imaging Collaboration Agreement
15 April 2024, IXICO plc (AIM: IXI), London, UK, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials.
Imeka Collaboration Agreement
3 April 2024, IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces a collaboration agreement with IMEKA Solutions Inc. ("Imeka") to provide access to Imeka's suite of services for white matter1 imaging deployed in Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, amongst other CNS indications.
Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants
Summary: For HD-ISS Stage 2 and Stage 3 participants, whole-brain volume shows significant association with clinical change for all four clinical variables examined here. For caudate and putamen volume, the association depended on the clinical variable. Our results provide further evidence on the use of volume change as a surrogate endpoint.
Comparison of amyloid positivity and global cortical SUVR between black and white non-Hispanic participants in the GAP Bio-Hermes study
Summary: This poster shows our further investigation on the amyloid PET differences between Black and White participants in the GAP Bio-Hermes study and to better understand the relationship between Aβ+ status from visual read and quantitative SUVR.
A convolutional neural network-based framework for imaging biomarkers in MS - white matter hyperintensity & brain region volumes ECTRIMS 2023
Summary: We developed and validated scalable and robust methods for automated volumetric analysis of brain white matter hyperintensities (T2 lesions) and regions of interest in multiple sclerosis.
The impact of diversity on Alzheimer's disease clinical trial design
Lammert Albers, Chief Commercial Officer of the Global Alzheimer's Platform Foundation talks with John Dwyer, President of the foundation, and our Chief Scientific Officer, Robin Wolz about the impact of this study diversity on current and future research and the opportunities at hand at the upcoming CTAD Clinical Trials on Alzheimer's Disease 2023 conference in Boston.
1-8 of 133 results